SCHEMBL7069908

SCHEMBL7069908

CCCCCCc1ccc2[nH]c(=O)cc(C)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CTSV O60911 2/20 0.49
▸ CTSL P07711 2/20 0.49
▸ HTR1A P08908 1/20 0.49
▸ HTR1D P28221 1/20 0.49
▸ HTR1B P28222 1/20 0.49
▸ UNG P13051 3/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ GPR84 Q9NQS5 2/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ TNKS2 Q9H2K2 1/20 0.46
▸ GHSR Q92847 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7074282 0.98 LMNA (0.51) LMNAHPGDCYP2C9CTSVCTSL
SCHEMBL11007109 0.86 GPR84 (0.51) CTSVCTSLHTR1AHTR1DHTR1B
SCHEMBL7290340 0.85 GPR84 (0.44) CTSVCTSLHTR1AHTR1DHTR1B
SCHEMBL17505188 0.84 LMNA (0.51) LMNAHPGDCYP2C9HTR1AHTR1D
SCHEMBL4581413 0.82 HTR1A (0.57) LMNACTSVCTSLHTR1AHTR1D
SCHEMBL31070057 0.82 HTR1A (0.57) LMNACTSVCTSLHTR1AHTR1D
SCHEMBL1128166 0.82 HTR1A (0.57) LMNACTSVCTSLHTR1AHTR1D
SCHEMBL12795553 0.82 HTR1A (0.57) LMNACTSVCTSLHTR1AHTR1D
SCHEMBL12100781 0.82 HTR1A (0.57) LMNACTSVCTSLHTR1AHTR1D
SCHEMBL31410497 0.82 HTR1A (0.57) LMNACTSVCTSLHTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176314-A1 Compounds for the treatment of pain H. LUNDBECK A/S (DK) 2003-09-18 — — US disclosed
US-20030139431-A1 Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors H. LUNDBECK A/S (DK) 2003-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176314-A1 Compounds for the treatment of pain NPFFR2, NPFFR1, OPRL1 LMNA 4829/4885HPGD 537/4885CYP2C9 4573/4885
US-20030139431-A1 Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors NPFFR1, NPFFR2, SSTR3 LMNA 2301/4885HPGD 3840/4885CYP2C9 3950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback